mochi compounded tirzepatide Health GLP-1 Review: Wide Shelf, Hidden Prices Losing Weight RX vs. Mochi

Ozempic maker Novo Nordisk said on Tuesday it is suing arch US rival Eli Lilly over false and materially misleading adverts for its competing weight-loss and anti-diabetes treatments

Safe, effective, and beautifully simple

This innovative treatment is typically recommended for individuals with obesity or those struggling to lose weight through traditional methods

Eli Lilly reiterated to NPR that the drugs have been "available since August." "Our current manufacturing investment of over $20 billion in the past four years is the most significant in our history, and will allow us to continue increasing capacity to safely bring these medicines to people who need them," Eli Lilly spokesperson Courtney Kasinger wrote in an email